Lonza Group AG
LONN
Rankning i aktier
#447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Aktiekurs
$764.04
Marknadsvärde
$53.36B
Förändring (1 dag)
0.96%
Förändring (1 år)
8.59%
Land
CH
Handel Lonza Group AG (LONN)
Kategori
Healthcare
Vinst för Lonza Group AG (LONN)
Vinst i 2026 TTM: 0
Enligt de senaste finansiella rapporterna från Lonza Group AG är företagets nuvarande vinst 0. År 2026 hade företaget en vinst på 0, lika med vinsten år 2026 som var 0. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Lonza Group AG från 2004 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2025 | $1.39B | 77.01% |
| 2024 | $783.78M | -16.56% |
| 2023 | $939.36M | -40.02% |
| 2022 | $1.57B | 87.88% |
| 2021 | $833.60M | -4.61% |
| 2020 | $873.87M | 18.24% |
| 2019 | $739.09M | -9.57% |
| 2018 | $817.28M | 49.73% |
| 2017 | $545.84M | 48.94% |
| 2016 | $366.48M | 7.42% |
| 2015 | $341.15M | 21.46% |
| 2014 | $280.87M | 138.68% |
| 2013 | $117.67M | -48.71% |
| 2012 | $229.45M | 23.16% |
| 2011 | $186.30M | -47.24% |
| 2010 | $353.12M | 96.17% |
| 2009 | $180.00M | -59.52% |
| 2008 | $444.71M | 39.23% |
| 2007 | $319.41M | 55.15% |
| 2006 | $205.88M | 36.16% |
| 2005 | $151.21M | -3.96% |
| 2004 | $157.45M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| $3.01B | - |
BE
|
